Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab-treated patients: comment on the article by Simon et al.
作者信息
Evangelatos Gerasimos, Kouna Konstantina, Fragoulis George E, Moschopoulou Melina, Triantafylli Maria, Lekka Antigoni, Iliopoulos Alexios
机构信息
First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
417 Army Share Fund Hospital (NIMTS), Athens, Greece.
出版信息
Arthritis Rheumatol. 2022 May;74(5):908-909. doi: 10.1002/art.42011. Epub 2022 Apr 5.
Abstract
摘要
相似文献
1
Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab-treated patients: comment on the article by Simon et al.
Arthritis Rheumatol. 2022 May;74(5):908-909. doi: 10.1002/art.42011. Epub 2022 Apr 5.
2
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
3
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
4
Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli .对博内利的《利妥昔单抗治疗患者的SARS-CoV-2疫苗接种：体液免疫受损但细胞免疫可诱导的证据》的通信回复 。
Ann Rheum Dis. 2021 Oct;80(10):e167. doi: 10.1136/annrheumdis-2021-220997. Epub 2021 Aug 2.
5
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
6
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.利妥昔单抗治疗患者对 COVID-19 疫苗接种产生体液免疫应答受损的风险因素。
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI163-SI168. doi: 10.1093/rheumatology/keab815.
7
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.利妥昔单抗治疗的淋巴瘤患者在接种 COVID-19 疫苗后会产生强烈的 CD8 T 细胞反应。
Br J Haematol. 2022 Jun;197(6):697-708. doi: 10.1111/bjh.18149. Epub 2022 Mar 21.
8
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.接受利妥昔单抗治疗的类风湿关节炎患者接种新型冠状病毒疫苗后特异性T细胞反应的存在情况。
Immunol Res. 2021 Aug;69(4):309-311. doi: 10.1007/s12026-021-09212-5. Epub 2021 Jul 29.
9
Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection.
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI191-SI193. doi: 10.1093/rheumatology/keac201.
10
Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity?B 细胞缺陷患者能否依赖 COVID-19 疫苗诱导的 T 细胞免疫？
Br J Haematol. 2022 Jun;197(6):659-661. doi: 10.1111/bjh.18210. Epub 2022 Apr 25.
引用本文的文献
1
Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study.COVID-19 奥密克戎变异株在类风湿关节炎患者中的结局：一项全国性希腊队列研究。
Rheumatology (Oxford). 2024 Apr 2;63(4):1130-1138. doi: 10.1093/rheumatology/kead354.
2
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.抗 TNF-a 治疗在临床实践中的第二个十年：COVID-19 时代的新经验教训和未来方向。
Rheumatol Int. 2022 Sep;42(9):1493-1511. doi: 10.1007/s00296-022-05136-x. Epub 2022 May 3.
本文引用的文献
1
Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy.进退两难：新冠病毒疫苗接种与接受利妥昔单抗治疗的患者
Leuk Lymphoma. 2021 Dec;62(12):2820-2822. doi: 10.1080/10428194.2021.1957879. Epub 2021 Jul 27.
2
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.在接受利妥昔单抗治疗的患者中接种 SARS-CoV-2 疫苗：B 细胞在 T 细胞介导的免疫存在下促进体液免疫反应。
Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20.
3
Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion.体液和细胞免疫对 B 细胞耗竭的自身免疫性疾病患者感染 SARS-CoV-2 及疫苗接种的反应。
Arthritis Rheumatol. 2022 Jan;74(1):33-37. doi: 10.1002/art.41914. Epub 2021 Nov 23.
4
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2.美国风湿病学会关于风湿和肌肉骨骼疾病患者 COVID-19 疫苗接种的指南：第 2 版。
Arthritis Rheumatol. 2021 Aug;73(8):e30-e45. doi: 10.1002/art.41877. Epub 2021 Jun 15.
5
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的反应原性、免疫原性和效力的比较系统评价与荟萃分析
NPJ Vaccines. 2021 May 13;6(1):74. doi: 10.1038/s41541-021-00336-1.
6
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局：一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
7
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
8
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.2019 年更新版：欧洲抗风湿病联盟成人自身免疫性炎症性风湿病患者疫苗接种推荐。
Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.
Zotero 插件